Affimed–Leucadia: investor conference, 202211 supply service Affimed presents at Jefferies 2022 London Healthcare Conference

	Period	2022-11-16
	Region	London, Greater London
	Country	United Kingdom (GB)
	Partner, 1st	Affimed N.V. (Nasdaq: AFMD)
	Group	Affimed (Group)
	Partner, 2nd	Jefferies International Ltd.
	Group	Leucadia (Group)
	Product	Jefferies 2022 London Healthcare Conference
	Product 2	ROCK® (Redirected Optimized Cell Killing) platform
	Person	Hoess, Adi (Affimed 201109– CEO before CCO before Jenowis + Jerini 2003– + Carl Zeiss AG + MorphoSys AG)
	Person 2	Fudukidis, Alexander (Alex) (Affimed 202005– Head IR before Synoes Health)

Affimed N.V.. (11/1/22). "Press Release: Affimed to Present at the 2022 Jefferies London Healthcare Conference". Heidelberg.

Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will present at the 2022 Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 12:55 p.m. GMT / 7:55 a.m. EST / 13:55 CET.

A live webcast of the presentation will be accessible on Affimed’s website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. A replay of the call will be archived on Affimed’s website for 30 days after the call.

For more information on the conference or to schedule a one-on-one meeting with Affimed management, please contact your Jefferies representative or Alex Fudukidis via email at a.fudukidis@affimed.com or phone at +1 (917) 436-8102.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to give patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE® ) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE® . Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.

Affimed Investor Contact

Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102